ClinicalTrials.gg
CompletedNCT01820806Updated May 7, 2013

Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

A Phase 1 interventional study of 100 mg dose of [14C] GLPG0634 in Healthy, sponsored by Galapagos NV. Completed at 1 site in United Kingdom. Open to male participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-07.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Male
01

Study summary

This will be a study in 6 healthy male subjects, each receiving a single oral dose of 100 mg [14C]-radiolabeled GLPG0634.

The study aims to establish the elimination pathways of GLPG0634 and their relative significance and to assess the metabolite profile of GLPG0634 in plasma and in excreta.

Furthermore, the pharmacokinetics (PK) of the main metabolites in plasma relative to GLPG0634 will be evaluated.

This study will also provide safety and tolerability information for GLPG0634.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male, between 40 and 65 years of age, inclusive
  • within range 18 to 30 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Any condition that might interfere with the procedures or tests in this study
  • Drug or alcohol abuse
  • Smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] GLPG0634

    Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion

    Drug: 100 mg dose of [14C] GLPG0634

Interventions

  • Drug100 mg dose of [14C] GLPG0634

    Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion

06

What researchers measure

Primary outcomes

  1. The amount of total radioactivity in urine and faeces over time after a single dose of radiolabeled GLPG0634

    To evaluate the mass balance recovery of total radioactivity in urine, faeces, and urine and faeces combined to determine the elimination pathways and their relative significance after a single dose of radiolabeled GLPG0634

    Time frame: Day -1 (pre-dosing) up to Day 10 post dosing

  2. The amount of GLPG0634 and its main metabolites in urine and faeces over time after a single dose of radiolabeled GLPG0634

    To evaluate the recovery of GLPG0634 and its main metabolites in urine and faeces after a single dose of radiolabeled GLPG0634 to determine the elimination pathways and their relative significance (excretion and renal clearance)

    Time frame: Day -1 (pre-dosing) up to Day 10 post dosing

  3. Identification of metabolites over time in plasma, urine and faeces after a single dose of radiolabeled GLPG0634

    Metabolite profiling and identification in plasma, urine and faeces over time after a single dose of radiolabeled GLPG0634

    Time frame: Day -1 (pre-dosing) up to Day 10 post dosing

  4. The amount of radioactivity, GLPG0634 and its main metabolites in blood and plasma over time after a single dose of radiolabeled GLPG0634

    To characterize the amount of radioactivity, GLPG0634 and its main metabolites in blood and plasma over time after a single dose of radiolabeled GLPG0634

    Time frame: Day 1 (pre-dosing) up to Day 8 post dosing

Secondary outcomes

  1. Number of adverse events

    To evaluate the safety and tolerability of GLPG0634 after a single dose of radiolabeled GLPG0634 in terms of the number of adverse events reported

    Time frame: Screening up to Day 10 post dosing

  2. Changes in vital signs as measured by heart rate, blood pressure and oral temperature

    To evaluate the safety and tolerability of GLPG0634 after a single dose of radiolabeled GLPG0634 in terms of changes in vital signs as measured by heart rate, blood pressure and oral temperature reported

    Time frame: Screening up to Day 10 post dosing

  3. Changes in 12-lead ECG measures

    To evaluate the safety and tolerability of GLPG0634 after a single dose of radiolabeled GLPG0634 in terms of changes in 12-ECG measures reported

    Time frame: Screening up to Day 10 post dosing

  4. Changes in physical exam measures

    To evaluate the safety and tolerability of GLPG0634 after a single dose of radiolabeled GLPG0634 in terms of changes in physical exam measures reported

    Time frame: Screening up to Day 10 post dosing

  5. Changes in blood safety lab parameters

    To evaluate the safety and tolerability of GLPG0634 after a single dose of radiolabeled GLPG0634 in terms of changes in blood safety lab parameters reported

    Time frame: Screening up to Day 10 post dosing

  6. Changes in urine safety lab parameters

    To evaluate the safety and tolerability of GLPG0634 after a single dose of radiolabeled GLPG0634 in terms of changes in urine safety lab parameters reported

    Time frame: Screening up to Day 10 post dosing

07

Study locations

1 site
  • Quotient Clinical
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2013
First posted
Mar 29, 2013
Start
Mar 2013
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
May 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01820806
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Mar 29, 2013
Start date
Mar 2013
Primary completion
Apr 2013
Completion
Apr 2013
Last update
May 7, 2013

Study contacts

Frédéric - Vanhoutte, MD
study director · Galapagos NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion